Yara A. Khatib

Yara A. Khatib

Auto-generated profile, based on publicly available information

Yara A. Khatib

Institute for Psychedelics and Neurotherapeutics, University of California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JTJeremy R. Tuck
Jeremy R. Tuck
LDLee E. Dunlap
Lee E. Dunlap
YKYara A. Khatib
Yara A. Khatib
CHCassandra J. Hatzipantelis
Cassandra J. Hatzipantelis
SNSammy Weiser Novak
Sammy Weiser Novak
DODavid E. Olson
David E. Olson
Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the molecular design and de novo total synthesis of (+)-JRT, a structural analogue of lysergic acid diethylamide (LSD) with lower hallucinogenic potential and potent neuroplasticity-promoting properties. In addition to promoting spinogenesis in the cortex, (+)-JRT produces therapeutic effects in behavioral assays relevant to depression and cognition without exacerbating behavioral and gene expression signatures relevant to psychosis. This work underscores the potential of nonhallucinogenic psychoplastogens for treating diseases where the use of psychedelics presents significant safety concerns.

30 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHCassandra J. Hatzipantelis
Cassandra J. Hatzipantelis
MLMin Liu
Min Liu
ALAdam Love
Adam Love
SLSadie J. Leventhal
Sadie J. Leventhal
HMHero Maera
Hero Maera
DSDanielle S. Stolzenberg
Danielle S. Stolzenberg
Psilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders. However, the efficacy and safety of psilocybin in peripartum mood disorders has not been investigated. We used a social stress model to examine the effects of psilocybin in parous mice and their offspring. Social stress induced maternal withdrawal and increased stress-related behaviors – none of which were ameliorated by psilocybin. Weeks later, psilocybin-treated dams were more anxious, regardless of stress exposure. In contrast, psilocybin-treated virgin females were unaffected. Though reproductive status did not affect psilocybin pharmacokinetics, serotonin receptor transcription and 5-HT2A receptor-dependent responses were reduced in dams. Offspring exposed to maternal psilocybin during breastfeeding exhibited anhedonia in adulthood. Here, we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period.

8 September 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ABAndrian G. Basargin
Andrian G. Basargin
ADAndras Domokos
Andras Domokos
JHJoseph J. Hennessey
Joseph J. Hennessey
IAIsak K. Aarrestad
Isak K. Aarrestad
RSRohini Sambyal
Rohini Sambyal
DODavid E. Olson
David E. Olson
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in pharmacological assays relevant to 5-HT2A, 5-HT2B, and 5-HT2C receptor function. Our work revealed the key molecular features and minimal pharmacophore of LSD necessary to produce maximal agonism of 5-HT2A receptors and hallucinogenic behavioral effects. Furthermore, we established strategies for reducing the hallucinogenic and cardiotoxic potential of LSD and identified UCD0094 and UCD0076 as ergologs with improved safety profiles. In stark contrast to LSD, UCD0076 exhibits preference for activating 5-HT2C receptors over other 5-HT2 receptors and produces antipsychotic-like properties in mouse behavioral assays.